Portal de Periódicos da CAPES

Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors

2011; BioMed Central; Volume: 8; Issue: 1 Linguagem: Inglês

10.1186/1743-422x-8-40

1743-422X

Ran He, Gordon Sandford, Gary S. Hayward, William H. Burns, Gary H. Posner, Michael Forman, Ravit Arav‐Boger,

Biosensors and Analytical Detection

Recombinant Towne CMV expressing luciferase under the control of CMV-DNA polymerase (POL) or the late pp28 (UL99) promoters were evaluated for potential application in high-throughput screening of anti-viral compounds. POL-and pp28-luciferase displayed maximal expression 48 and 72 hours post infection, respectively. The pp28-luciferase virus achieved a wider dynamic range of luciferase expression (6-7 logs) and was selected for testing of inhibition by five anti-viral compounds. Luciferase expression highly correlated with plaque reduction and real-time PCR. The pp28-luciferase reporter system is rapid, reproducible, and highly sensitive. It may be applied to screening of novel anti-CMV compounds.